morning, Thank good everyone. you, operator, and
Our two included ago Stereotaxis months last of strategy. our a and call fairly comprehensive overview
on We a brief, few today's innovation and keep will focusing updates. call commercial more
year's was from the quarter reflects barring essentially System first first the that last we receive quarter, recognition shipment royalty to longer revenue in system speak. Genesis Johnson is that payments on Revenue one partial revenue quarter the installation identical completing we Johnson. of in no the & as
subsequent call, We hospital. so from quarter last for far our order purchase this first order we a another Genesis the system a earnings a quarter. Europe Genesis system During and from received received U.S. to
backlog out of a installed the system just combination installs The and Hospital increased revenue as over this converts then backlog backlog be we the quarter schedule our expect to relatively the robots. to year. weighing speed $XX backlog planned construction recognized backlog on our partial continue revenue order which with end busy to into slow, million. revenue recognition into and said, That have our over remained into the months slightly fairly has of of and system active coming majority of additional
the infrastructure turnaround customer required years are be orders but shipped capital have for five period installed over the two sales when is XX three shipped. not frame. has are or we hospital launched ordered to and Genesis orders our now the Building robots ago, have over since installed remain a a was years robotic the time Since of process but in been to and procedures, have these to XX dramatic prior launch, one significant time taken system been Genesis waiting nine from and Of the launch eight effort, received capability, XX ordered and same only doing yet backlog systems.
Our broad-based and just the over evenly They and split are approximately from from States United of been each XX% orders orders XX% geographically XX Asia. and with robots between with each. of have Europe also upgrades greenfield
Genesis. improve and and to continuing expect to our so are capabilities do We of as commercial refine see increasing we orders
seen across Our capital regions. and has focus three pipeline looks our growth healthy
increasing near-term there's where We up, cycle. not possible still dozen, But consistent flow orders. from in lumpy. from pipeline have a few unique and pressured, a XX given a bottom normalized received Order benefited months. fully we order environment over see approximately of the the The have in our next engagement we a remains opportunities XX remains the macro replacement flow confidence
the are practices able successful customers historical to patients change Most value important increase best through ultimately along the who experience grow the demonstrating of awareness, are physicians enthusiastically in to who robots clinical to provide and Genesis and to care Genesis adoption the and of using the are positive reliability robotics their and great with field. happy adoption. the are ambassadors build which Engaged is misperceptions
both those are Genesis We utilization. Last global those ways excited are to like seeing using meaningfully National quality and the robots, improve the to most is upgraded the Discussions impact of the relevance of technology patients (ph). average reinforce accounts are and launches, the utilization to This procedure with both and care. a we and to at treat higher practices. for Center recent that happy is of our new pleased technology establish out meaningfully Medical opportunity than [field] importance greenfield grateful Institute it two on Health which for that Fort Genesis from with that had entirely month, and of robotics positive robotic Poland's the physicians Cardiology are Where Genesis in of be meet our I playing and in our Lauderdale. and our users care who Broward access
able detail with as capital results. on into Our the how our impact restart most spark they technology support of been our strategic call, for in overall innovation. to to and a the to adoption meaningful clinical, experience is catheter, same last segues our reminder efforts positively robotic On commercial Stereotaxis' essentially significant to over catheter innovation and Genesis, robotically and utilization of using have it. strategic discussed from deliver who to robot, mapping electrophysiologists the decade. well concept limited has Genesis ablation minority is a we few a plan serving innovation navigated commercial and the key MAGiC, ecosystem users in existing proprietary This the have and address to set upgrade of Apart value. remained
on of EU we progress the regulatory and microbiology last have paths significant regulator. Europe, clinical MAGiC. of receipt technical, from both U.S. full call, our the and questions made spectrum Since awaiting for have we In EU been the
previously surprised comprehensive across have and of questions still of CE in would and likely I the most those follow-up in thoughtful categories We would questions questions the responses, all we or to occur it have we to what to all to time communicated of -- not surprising believe in Mark reasonable receipt but not see three be our Mark. as manner second quarter received believe receive late fully is summertime. be to now line the CE responded a be supportive and our
the been dozen the a studies. has dependent IDE preclinical In FDA to completing an successfully application submission on U.S., of
and have that very ago, had on well and animal program since GLP-level pilot seen have we physician that required robotic We the we established The is we the will required enthusiastically a results adopted feedback confidence the performs within be call all two of institutional community the record and cases our complete received next all catheter two our use of studies run will the by As few the care not and of follow-up periods those users. weeks. a performed call months and yet completed studies. but supportive
Given this make the we submission quarter. in to progress, IDE to an third the expect FDA
innovation smaller necessary guide from full parallel. and is being construction of each ecosystem including in self-shielding software made enabling that digital MicroPort. adopt extensive operating product progress a that room and of expand electrophysiology indications, robotics, built offering, major a connectivity benefits in catheters work being a to collaboration a on and our us planning There with a other surgery, amount and of Our hardware guidewires significant these endovascular in efforts, the robot of new currently frees family broad the robot into interventional
reiterate provided that time of on call more much we lines I'll call, each As stand. last on our that during the color these communicated just
next have each of commercial technologies We of growing these with impact multiple sight to significant line and reaching from year this regulatory milestones year. commercial
these host As we market, technologies in to focused come detail. to days innovation will technologies present greater these
financial While unexciting, optics strategic as ourselves cusp of the see the of being are we transformation. Stereotaxis' on results
company ecosystem We indication have accessibility with pioneering clear and future for revenue a high-value medtech line broad core of high-growth, This attractive foundation sight to platform model, as robotics. endovascular a serves product an strategic opportunity. a robot independence,
call financial few then make will will to commentary results, our on I now as a comments Kim Q&A. some financial opening well and provide the before
